The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
The ED50 determined by a cytotoxicity assay using HT-29 cells is ≤0.05 ng/mL, corresponding to a specific activity of ≥ 2 x 107 units/mg.
< 1.000 Eu/µg
% SDS-PAGE. Sterile filtered. Greater than 97% by SDS-PAGE and HPLC analyses.
Concentration information loading...
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Centrifuge vial prior to opening. Reconstitute in 100 µl 1x PBS, pH 8.0 to a concentration of 1.0 mg/ml. Do not vortex.
Long term storage: Follow reconstitution with further dilution in a buffer containing a carrier protein (example; 0.1% BSA).
Store working aliquots at -20°C to -80°C. Avoid repeated freeze-thaw cycles.
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Released primarily from activated T lymphocytes.
In Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.
Belongs to the type II (or gamma) interferon family.
Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.